BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 29602820)

  • 1. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.
    Zettlitz KA; Tsai WK; Knowles SM; Kobayashi N; Donahue TR; Reiter RE; Wu AM
    J Nucl Med; 2018 Sep; 59(9):1398-1405. PubMed ID: 29602820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Zettlitz KA; Tsai WK; Knowles SM; Salazar FB; Kobayashi N; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Apr; 22(2):367-376. PubMed ID: 31209779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Dual-Modality Linker Enables Site-Specific Conjugation of Antibody Fragments for
    Zettlitz KA; Waldmann CM; Tsai WK; Tavaré R; Collins J; Murphy JM; Wu AM
    J Nucl Med; 2019 Oct; 60(10):1467-1473. PubMed ID: 30877181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody.
    Tsai WK; Zettlitz KA; Tavaré R; Kobayashi N; Reiter RE; Wu AM
    Theranostics; 2018; 8(21):5903-5914. PubMed ID: 30613270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time.
    Sonn GA; Behesnilian AS; Jiang ZK; Zettlitz KA; Lepin EJ; Bentolila LA; Knowles SM; Lawrence D; Wu AM; Reiter RE
    Clin Cancer Res; 2016 Mar; 22(6):1403-12. PubMed ID: 26490315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
    Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.
    Lepin EJ; Leyton JV; Zhou Y; Olafsen T; Salazar FB; McCabe KE; Hahm S; Marks JD; Reiter RE; Wu AM
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1529-38. PubMed ID: 20354850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.
    Knowles SM; Zettlitz KA; Tavaré R; Rochefort MM; Salazar FB; Stout DB; Yazaki PJ; Reiter RE; Wu AM
    J Nucl Med; 2014 Mar; 55(3):452-9. PubMed ID: 24504052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models.
    Zhang M; Kobayashi N; Zettlitz KA; Kono EA; Yamashiro JM; Tsai WK; Jiang ZK; Tran CP; Wang C; Guan J; Wu AM; Reiter RE
    Clin Cancer Res; 2019 Jan; 25(1):188-200. PubMed ID: 30301826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET/CT and NIRF.
    Hall MA; Pinkston KL; Wilganowski N; Robinson H; Ghosh P; Azhdarinia A; Vazquez-Arreguin K; Kolonin AM; Harvey BR; Sevick-Muraca EM
    J Nucl Med; 2012 Sep; 53(9):1427-37. PubMed ID: 22872743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomographic imaging of iodine 124 anti-prostate stem cell antigen-engineered antibody fragments in LAPC-9 tumor-bearing severe combined immunodeficiency mice.
    Fonge H; Leyton JV
    Mol Imaging; 2013 May; 12(3):191-202. PubMed ID: 23490445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.
    Houghton JL; Zeglis BM; Abdel-Atti D; Aggeler R; Sawada R; Agnew BJ; Scholz WW; Lewis JS
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15850-5. PubMed ID: 26668398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer.
    Lütje S; Rijpkema M; Goldenberg DM; van Rij CM; Sharkey RM; McBride WJ; Franssen GM; Frielink C; Helfrich W; Oyen WJ; Boerman OC
    Cancer Res; 2014 Nov; 74(21):6216-23. PubMed ID: 25252911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer.
    Knowles SM; Tavaré R; Zettlitz KA; Rochefort MM; Salazar FB; Jiang ZK; Reiter RE; Wu AM
    Clin Cancer Res; 2014 Dec; 20(24):6367-78. PubMed ID: 25326233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.
    Hernandez R; Sun H; England CG; Valdovinos HF; Ehlerding EB; Barnhart TE; Yang Y; Cai W
    Theranostics; 2016; 6(11):1918-33. PubMed ID: 27570560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer.
    Foss CA; Fox JJ; Feldmann G; Maitra A; Iacobuzio-Donohue C; Kern SE; Hruban R; Pomper MG
    Mol Imaging; 2007; 6(2):131-9. PubMed ID: 17445507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models.
    Kasten BB; Jiang K; Cole D; Jani A; Udayakumar N; Gillespie GY; Lu G; Dai T; Rosenthal EL; Markert JM; Rao J; Warram JM
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1412-1426. PubMed ID: 31773232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.